Skip Navigation


European Journal of Echocardiography Advance Access originally published online on March 26, 2009
European Journal of Echocardiography 2009 10(4):467-476; doi:10.1093/ejechocard/jep023
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
10/4/467    most recent
jep023v2
jep023v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Droogmans, S.
Right arrow Articles by Van Camp, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Droogmans, S.
Right arrow Articles by Van Camp, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Role of echocardiography in toxic heart valvulopathy

Steven Droogmans1,2, Dirk Kerkhove1, Bernard Cosyns1,2 and Guy Van Camp1,2,*

1 Cardiology Department, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Belgium
2 In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Jette, Belgium

Received 6 February 2009; accepted after revision 1 March 2009; online publish-ahead-of-print 26 March 2009.

* Corresponding author. Tel: +32 24776009; fax: +32 24776851. E-mail address: guy.vancamp{at}uzbrussel.be


  Abstract

The notion that drugs can induce valvular heart disease (VHD) has occurred since the 1960s and has received a lot of attention in recent years. This review focuses on different aspects of this distinct valvulopathy in seven sections: (i) historical background, (ii) drug-induced VHD, is this a real entity?, (iii) its morphological and echocardiographic features, (iv) drugs associated with VHD, (v) the influence of cumulative drug dose and risk factors, (vi) the natural course of toxic valvulopathy, and (vii) practical recommendations when using potential valvulopathic drugs.

Keywords: Echocardiography; Toxic valvulopathy; Anorexigens; Ergot-derived dopamine agonists; Amphetamines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.